Study guide
9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
Key Takeaways Explain This Topic AI
Dermatitis herpetiformis (DH, Duhring's disease) is the cutaneous manifestation of gluten-sensitive enteropathy (coeliac disease), characterized by intense stinging/burning pruritus, symmetrical grouped polymorphic vesicles on extensor surfaces, and almost universal linkage to HLA-DQ2 (95%) and HLA-DQ8 (5%).
The definitive diagnostic gold standard for dermatitis herpetiformis is direct immunofluorescence (DIF) demonstrating granular IgA deposits located in the dermal papillae tips of perilesional, normal-appearing skin; sampling the blister itself results in false-negative findings due to elastase degradation.
A strict, lifelong gluten-free diet (GFD) is the only curative and disease-modifying treatment for dermatitis herpetiformis, healing both intestinal villous atrophy and cutis and is thought to reduce the elevated risk of enteropathy-associated T-cell lymphoma (EATL).
Dapsone produces dramatic suppression of cutaneous symptoms in dermatitis herpetiformis within 24 to 72 hours, but mandates pre-treatment glucose-6-phosphate dehydrogenase (G6PD) deficiency screening to avert life-threatening acute hemolytic crisis.
Linear IgA bullous dermatosis (LABD) is distinguished by homogeneous linear IgA deposition along the basement membrane zone targeting the 97-kDa or 120-kDa (LAD-1) shed ectodomains of BP180, often featuring 'string-of-pearls' annular bullae and strongly linked to vancomycin exposure.
Last updated: September 2026
- 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
- Dermatitis Herpetiformis (DH, Duhring's Disease)
Dermatitis herpetiformis (DH) is an intensely pruritic, chronic, polymorphic autoimmune blistering dermatosis that serves as the specific cutaneous manifestation of gluten-sensitive enteropathy (coeliac disease) . First described by Louis Duhring in 1884, DH represents an immunologically driven model of mucosal tolerance breakdown and gut-skin cross-talk.
Immunopathogenesis & The Gut-Skin Axis
Genetic Architecture: Like coeliac disease, DH exhibits the strongest human leukocyte antigen (HLA) class II genetic association known in dermatology:
HLA-DQ2.5 (encoded by alleles D Q A 1 ∗ 05 : 01 DQA1*05:01 D Q A 1 ∗ 05 : 01 and D Q B 1 ∗ 02 : 01 DQB1*02:01 D QB 1 ∗ 02 : 01 ) is present in 90% to 95% of patients.
HLA-DQ8 (encoded by alleles D Q A 1 ∗ 03 : 01 DQA1*03:01 D Q A 1 ∗ 03 : 01 and D Q B 1 ∗ 03 : 02 DQB1*03:02 D QB 1 ∗ 03 : 02 ) is present in the remaining 5% to 10% .
An individual who lacks both HLA-DQ2 and HLA-DQ8 has an essentially zero probability of developing dermatitis herpetiformis (negative predictive value >99%).
The Mucosal Trigger: Ingestion of dietary gluten (wheat gliadin, barley hordein, and rye secalin). Gliadin peptides resist complete proteolytic digestion by gastric and pancreatic enzymes. Proline- and glutamine-rich 33-mer gliadin peptides cross the intestinal epithelial barrier into the lamina propria.
Transglutaminase Enzymatic Deamidation: In the gut, tissue transglutaminase (tTG / TG2) enzymatically deamidates glutamine residues in gliadin into negatively charged glutamic acid. This modification drastically increases gliadin peptide binding affinity to positively charged peptide-binding grooves of HLA-DQ2/DQ8 heterodimers on antigen-presenting dendritic cells.
Autoantibody Generation & Epitope Spreading: Antigen presentation stimulates CD4+ T helper cells (Th1 and Th17), driving mucosal B-cell clonal expansion and synthesis of IgA autoantibodies directed against tTG. Through B-cell intramolecular and intermolecular epitope spreading, autoantibodies develop against epidermal transglutaminase (eTG / TG3) , an enzyme expressed in epidermal spinous keratinocytes involved in cornified envelope assembly.
Dermal Papillae Immune Complex Deposition: High-affinity circulating IgA-TG3 immune complexes deposit selectively within the tips of dermal papillae in the skin, where they bind to dermal fibrinogen and extracellular matrix microfibrils. These immune complexes activate complement (C3a and C3b generation), triggering local release of IL-8 and leukotriene B4 ( L T B 4 LTB_4 L T B 4 ). Neutrophils expressing high levels of the Fc-alpha receptor I (CD89) are recruited to the dermal papillae tips, releasing elastase, matrix metalloproteinases, and reactive oxygen species that cleave the lamina lucida, culminating in subepidermal blister separation.
Clinical Presentation of Dermatitis Herpetiformis
Symptom Hallmark: Characterized by excruciating, intense, burning, stinging, and lancinating pruritus . The itching is so severe and distinctive that patients frequently describe a painful sensation of "hot needles" or burning prior to any visible skin lesion erupting.
Morphology: The primary eruption is classically polymorphic : grouped, tiny, clustered vesicles resembling herpes simplex (hence the historical moniker herpetiformis ), alongside erythematous urticarial papules and small wheals.
Secondary Excoriations: Because the pruritus is intolerable, patients vigorously excoriate and scratch the skin. Consequently, intact primary vesicles are rarely observed in clinical practice. The patient typically presents with grouped, excoriated crusts, erosions, and post-inflammatory hypopigmentation or hyperpigmentation.
Anatomical Distribution: Strikingly symmetrical predilection for the extensor surfaces of the body:
Extensor elbows (olecranon prominence) and dorsal forearms.
Knees (patellar region) and pretibial shins.
Buttocks, sacrum, and natal cleft .
Upper back, posterior shoulders, and posterior scalp / nape of neck .
Mucous membrane involvement is virtually non-existent.
Intestinal Pathology and Malignancy Risk
Coeliac Enteropathy: Virtually all patients with dermatitis herpetiformis have gluten-sensitive small bowel enteropathy (around three-quarters show villous atrophy on duodenal biopsy; the rest show milder changes), ranging from mild Marsh I (intraepithelial lymphocytosis) to Marsh III (crypt hyperplasia with partial or total villous atrophy).
The "Silent" Gut Trap: Although enteropathy is universal, over 70% to 80% of DH patients have no overt gastrointestinal symptoms (no chronic diarrhea, bloating, or abdominal cramping). The absence of bowel complaints does NOT rule out DH or coeliac disease.
Enteropathy-Associated T-Cell Lymphoma (EATL): Patients with untreated DH or poor dietary compliance carry an elevated relative risk of developing Enteropathy-Associated T-Cell Lymphoma (EATL) , a highly aggressive intestinal non-Hodgkin lymphoma arising from intraepithelial T lymphocytes in the jejunum. Strict adherence to a lifelong gluten-free diet reverses intestinal mucosal inflammation, restores normal villous architecture, and, in cohort studies, appears to reduce the elevated lymphoma risk .
Diagnostic Workup in Dermatitis Herpetiformis
Direct Immunofluorescence (DIF) — The Diagnostic Gold Standard:
Biopsy Site Selection (Critical Technical Rule): The punch biopsy for DIF MUST be taken from perilesional, normal-appearing skin (1 to 2 cm adjacent to an active lesion). If the biopsy is mistakenly taken from an active blister or erosion, the massive influx of activated neutrophils will enzymatically degrade the bound IgA via elastase release, producing a false-negative DIF result .
DIF Pattern: Shows continuous or discontinuous granular deposits of IgA concentrated within the tips of the dermal papillae (fibrillar or granular pattern). Less commonly, granular IgA is deposited in a continuous band along the basement membrane zone. C3 is co-deposited in 50% of cases.
Histopathology (Routine H&E):
Biopsy of an early, intact erythematous papule or edge of a microvesicle demonstrates neutrophilic microabscesses clustered at the tips of dermal papillae. Accompanied by edema, fibrin deposition, leukocytoclasia, and occasional eosinophils. Confluence of microabscesses leads to subepidermal clefting at the lamina lucida.
Serological Testing:
IgA Anti-Epidermal Transglutaminase (Anti-eTG / Anti-TG3) ELISA: Highest sensitivity (>95%) and specificity (>98%) for dermatitis herpetiformis. Titer levels reflect cutaneous disease activity and dietary compliance.
IgA Anti-Tissue Transglutaminase (Anti-tTG / Anti-TG2) ELISA: High sensitivity; standard first-line coeliac screening test.
IgA Anti-Endomysial Antibodies (EMA): Detected by indirect immunofluorescence on primate esophagus (reticular staining of smooth muscle endomysium); extraordinarily high specificity (>99%).
Mandatory Serum Total IgA Determination: Selective IgA deficiency occurs at a 10- to 15-fold higher frequency in coeliac/DH patients (approx. 2–3% prevalence) than in the general population. In IgA deficiency, all IgA-based serologies (anti-tTG, anti-TG3, EMA) are falsely negative . If total serum IgA is subnormal, the clinician must order IgG anti-tTG , IgG anti-deamidated gliadin peptides (DGP) , and IgG anti-TG3 .
European Management Protocol: Dietary vs Pharmacological Strategy
Management rests on a dual strategy: life-saving dietary modification coupled with rapid-acting pharmacotherapy. Dermatitis Herpetiformis Management
- │
- ┌────────────────────────────────┴────────────────────────────────┐
- ▼ ▼
- Lifelong Gluten-Free Diet (GFD) Dapsone Pharmacotherapy
- Curative & Disease-Modifying - Rapid Symptomatic Control
- Heals small bowel villous atrophy - Suppresses burning/itching in 24–48h
- Prevents intestinal T-cell lymphoma - ZERO effect on bowel pathology
- Clears cutaneous IgA slowly (1–2 yrs) - Mandatory pre-treatment G6PD screening
Strict Lifelong Gluten-Free Diet (GFD):
The ONLY curative and disease-modifying treatment. Involves complete dietary exclusion of wheat, barley, and rye. Pure, uncontaminated oats are tolerated by the majority of patients.
Divergent Recovery Kinetics: While gastrointestinal mucosal architecture normalizes within 6 to 12 months, cutaneous IgA deposits clear extraordinarily slowly . Skin lesions require 1 to 2 years of strict GFD to resolve completely without medication. Patients must be counseled that even minor dietary indiscretions (e.g., a single crouton) can prompt an explosive cutaneous relapse within 24 to 72 hours.
Dapsone (Diaminodiphenylsulfone):
Mechanism: A sulfone antibiotic that potently suppresses neutrophil myeloperoxidase, inhibits neutrophil chemotaxis, and blocks integrin-mediated neutrophil adhesion and lysosomal enzyme release. Dapsone has zero effect on intestinal pathology and does not reduce lymphoma risk.
Clinical Efficacy: Produces dramatic, miraculous relief of burning and itching within 24 to 48 hours , with complete cessation of new blister formation within 72 hours. Serves as a diagnostic therapeutic trial.
Dosing: Initiated at 50 mg daily, titrated upward to 100 to 150 mg/day until symptoms are arrested, then tapered to the lowest effective maintenance dose (often 25–50 mg twice weekly) as the gluten-free diet takes effect over 1 to 2 years.
Mandatory Pre-Treatment Screening:
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Mandatory prior to writing the first dapsone prescription. In G6PD-deficient erythrocytes, dapsone's toxic N-hydroxy hydroxylamine metabolites cannot be reduced by glutathione, precipitating life-threatening, massive acute intravascular hemolytic crisis.
Predictable & Idiosyncratic Adverse Effects:
Dose-Dependent Hemolysis & Methemoglobinemia: Every patient taking dapsone experiences mild, predictable, dose-dependent oxidative hemolysis and methemoglobinemia (Fe2+ oxidized to Fe3+, shifting the oxygen-hemoglobin dissociation curve to the left and impairing tissue oxygenation). Standard pulse oximeters measure falsely low (reading ~85%); co-oximetry on arterial blood gas is required for accurate quantification. Cimetidine (which inhibits CYP2C9 conversion of dapsone to hydroxylamine) reduces methemoglobin levels.
Agranulocytosis: Rare (1 in 2000 to 5000), idiosyncratic, potentially fatal; typically arises within the first 2 to 12 weeks of treatment. Complete blood counts must be monitored every 2 weeks for the first 3 months.
Dapsone Hypersensitivity Syndrome (DHS / DRESS): Fever, exfoliative dermatitis, generalized lymphadenopathy, hepatitis, and eosinophilia.
Distal Motor Neuropathy: Rare, late complication causing motor weakness (e.g., hand weakness, wrist drop) without sensory loss.
Alternative Therapies (in Dapsone-Intolerant Patients):
Sulfasalazine (1.0–4.0 g/day), Sulfapyridine (1.0–2.0 g/day), or Sulfamethoxypyridazine .
Linear IgA Bullous Dermatosis (LABD)
Linear IgA bullous dermatosis is an acquired, autoimmune, subepidermal blistering disorder mediated by homogeneous, linear deposition of IgA autoantibodies along the basement membrane zone .
Epidemiology & Clinical Phenotypes
Two distinct clinical presentations are recognized:
Chronic Bullous Disease of Childhood (CBDC):
Peak onset occurs in preschool children between 2 and 5 years of age .
Follows a relatively benign, self-limiting course, typically remitting spontaneously within 2 to 4 years.
Blister distribution shows a predilection for the lower abdomen, perineum, genitalia, perioral face, and inner thighs .
Adult Linear IgA Bullous Dermatosis:
Most adult cases begin after 60 years (overall, LABD has a bimodal age distribution: preschool children and older adults).
Eruption involves the extensor limbs, trunk, face, and scalp.
Mucosal Involvement (up to 50%): Can produce painful desquamative gingivitis, oral ulcerations, and progressive conjunctival scarring mimicking cicatricial pemphigoid .
Morphological Hallmark: The "String-of-Pearls" Configuration
The pathognomonic clinical feature of LABD is the eruption of tense, clear or hemorrhagic vesicles and bullae arranged in an annular, polycyclic, or rosette-like pattern . Characteristically, new blisters erupt along the active erythematous periphery of resolving central crusted lesions—a classic morphology termed the "crown of jewels" or "string-of-pearls" sign .
Molecular Target Antigens
The circulating IgA autoantibodies in LABD target neoepitopes on soluble fragments of the extracellular ectodomain of BP180 (type XVII collagen) , which are shed following physiological physiological proteolytic cleavage by ADAM-family metalloproteinases:
LAD-1 (120 kDa): The full-length shed soluble ectodomain of BP180.
LABD97 (97 kDa): A truncated carboxy-terminal fragment derived from LAD-1.
Drug-Induced Linear IgA Bullous Dermatosis
LABD has the highest frequency of drug causation among all autoimmune bullous diseases:
The Hallmark Culprit: Vancomycin. Intravenous vancomycin is responsible for >50% of all drug-induced LABD cases worldwide. Eruptions typically emerge 1 to 15 days after initiating vancomycin therapy.
Clinical Presentation: Often severe, widespread, and explosive, frequently mimicking toxic epidermal necrolysis (TEN) or erythema multiforme with sheet-like epidermal sloughing.
Other Culprit Medications: Non-steroidal anti-inflammatory drugs (diclofenac, naproxen), captopril, ceftriaxone, amiodarone, phenytoin, and lithium.
Resolution: Withdrawal of the offending drug leads to rapid cessation of new blistering within 48 to 72 hours, with complete cutaneous healing over 2 to 6 weeks without recurrence.
Diagnostic Distinction & Management
Direct Immunofluorescence (DIF): Diagnostic hallmark. Shows continuous, homogeneous, linear IgA deposition along the basement membrane zone . (Distinguishes LABD from the granular IgA of dermatitis herpetiformis and the linear IgG/C3 of bullous pemphigoid).
Histopathology: Subepidermal blister with a dense neutrophilic infiltrate aligned along the BMZ and in dermal papillae tips, histologically indistinguishable from early dermatitis herpetiformis.
First-Line Therapy: Dapsone (50–150 mg/day in adults; 1–2 mg/kg/day in children) after confirming normal G6PD status. Corticosteroids can be co-administered in refractory cases.
Differential Diagnosis of Immunobullous Diseases
Disease Entity Primary Autoantigens Direct Immunofluorescence (DIF) Salt-Split IIF (1M NaCl) Clinical Hallmark Morphology First-Line Therapy
Dermatitis Herpetiformis (DH) Epidermal transglutaminase (eTG/TG3) Granular IgA in dermal papillae tips (perilesional skin) Negative (no circulating BMZ antibodies) Symmetrical grouped excoriated vesicles on extensor elbows/knees/buttocks Strict Gluten-Free Diet (GFD) + Dapsone
Linear IgA Dermatosis (LABD) BP180 shed ectodomains (LAD-1 120kDa, LABD97) Continuous linear IgA along BMZ Epidermal Roof (IgA) in 60–70% Annular "string-of-pearls" / rosette-like tense bullae Dapsone (withdraw vancomycin if drug-induced)
Bullous Pemphigoid (BP) BP180 (NC16A) & BP230 Continuous linear IgG & C3 along BMZ (n-serrated) Epidermal Roof (IgG) Tense blisters on urticarial base; severe elderly pruritus Whole-body Clobetasol Propionate cream
Epidermolysis Bullosa Acquisita Type VII Collagen (NC1 domain) Continuous linear IgG & C3 along BMZ (u-serrated) Dermal Floor (IgG) Trauma-induced acral blisters, scarring, milia High-dose steroids + Colchicine / Rituximab
Pemphigus Vulgaris (PV) Desmoglein 3 ± Desmoglein 1 Intercellular IgG & C3 throughout epidermis ("chicken-wire") Negative along BMZ (intercellular staining) Flaccid bullae, severe oral erosions, tombstoning Prednisolone 1.0 mg/kg + Rituximab 1000 mg